2025-2034 Huntington's Disease Treatment Market Outlook: Key Drivers, Emerging Challenges, and Strategic Insights

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Huntington's Disease Treatment Industry Market Size Be by 2025?
The market size for Huntington's disease treatment has seen a substantial increase in recent years. The expansion is projected from $0.73 billion in 2024 to $0.82 billion in 2025, with a compound annual growth rate (CAGR) of 12.3%. The notable growth during the historical period is primarily due to heightened awareness of genetic disorders, increased access to genetic testing, escalating investment in research for neurodegenerative diseases, a surge in clinical trials for exploratory therapies, and an increasing pipeline of disease-altering drugs.

What's the Long-Term Growth Forecast for the Huntington's Disease Treatment Market Size Through 2029?
Over the coming years, the market size for Huntington's disease treatment is expected to experience significant expansion. It's projected to reach $1.32 billion in 2029, with a compound annual growth rate (CAGR) of 12.6%. This projected growth within the timeline is due to several important factors such as the increasing emphasis on personalized medicine, augmented adoption of digital health monitoring, regulatory support for orphan drugs, a growing desire for symptom relief therapies, and an increased need for disease-altering treatments. Key trends during the forecast period will involve the use of technology-enhanced gene-silencing tools, development of cell-based therapies, creation of peripheral biomarkers, the implementation of telehealth in HD care, patient-reported outcomes integration, and innovations in disease-altering medication.

View the full report here:
https://www.thebusinessresearchcompany.com/report/huntingtons-disease-treatment-global-market-report

What Are the Key Growth Drivers Fueling the Huntington's Disease Treatment Market Expansion?
The surge in gene therapies is predicted to fuel the expansion of the Huntington's disease treatment market. These therapies, which alter or substitute faulty genes, serve as treatments to cure or avert diseases at their genetic core. The rise of gene therapies is synonymous with the progress of precision medicine, which provides enhanced results by directly targeting the genetic reasons compared to conventional treatments. The defective HTT gene causing Huntington's disease is silenced by gene therapies, avoiding the production of damaging proteins and preventing neuronal damage. This approach aids in the deceleration of the disease process, preserves brain functionality, and provides a scope for long-term control. For example, reports from the American Society of Gene & Cell Therapy (ASGCT) and Citeline, both US-based institutions, disclosed that in July 2023, 247 gene therapies were in phase II at the end of Q1 2023. However, there was a 5% increase, bringing the total to 260 by the end of Q2. Hence, the augmentation in gene therapies is spurring the growth of the Huntington's disease treatment market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24245&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Huntington's Disease Treatment Market?
Major firms in the Huntington's disease treatment market are concentrating on creating innovative therapies like selective vesicular monoamine transporter 2 (VMAT2) inhibitor capsules. These are designed to enhance the quality of life for patients and decelerate the disease's progress. Selective VMAT2 inhibitor capsules function by blocking the vesicular monoamine transporter 2, a protein that plays a role in packaging neurotransmitters intended for release in the brain. This helps mitigate the release of neurotransmitters, which assists in controlling involuntary movements and associated symptoms. For example, in August 2023, Neurocrine Biosciences, Inc., an American biotech company, was granted approval by the FDA for Ingrezza (valbenazine) capsules, intended to treat chorea linked with adult Huntington's disease. These capsules, administered once daily orally, help regulate involuntary movements by reducing the brain's excessive dopamine signaling. They are available in various strengths and can be consumed with or without food, making them a practical option for patients.

How Is the Huntington's Disease Treatment Market Segmented?
The huntington's disease treatment market covered in this report is segmented -

1) By Treatment: Symptomatic Treatment, Disease-Modifying Therapies
2) By Administration Type: Oral, Intravenous, Subcutaneous, Topical
3) By Therapeutic: Genetic Disorders, Neurological Disorders, Psychiatric Disorders
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Clinics, Homecare Settings, Research Centers

Subsegments:
1) By Symptomatic Treatment: Antidepressants, Antipsychotics, Mood Stabilizers, Chorea Medications, Cognitive Enhancers
2) By Disease-Modifying Therapies: Gene Therapy, Neuroprotective Agents, RNA-Based Therapies, Stem Cell Therapy, Protein-Targeting Therapies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24245&type=smp

Which Companies Are Leading the Charge in Huntington's Disease Treatment Market Innovation?
Major companies operating in the huntington's disease treatment market are F. Hoffmann-La Roche Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Bausch Health Companies Inc., Sun Pharmaceutical Industries Inc., H. Lundbeck A/S, WaVe Life Sciences Ltd., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Lupin Limited, Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Annexon Inc., Uniqure NV, Sage Therapeutics Inc., Azevan Pharmaceuticals Inc., Prilenia Therapeutics B.V.

Which Regions Are Leading the Global Huntington's Disease Treatment Market in Revenue?
North America was the largest region in the Huntington's disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the huntington's disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24245

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay,
Americas: +1 310-496-7795,
Asia: +44 7882 955267 & +91 8897263534,
Europe: +44 7882 955267,
Email: saumyas@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.